Literature DB >> 33774758

The Potential Role of miRNAs as Predictive Biomarkers in Neurodevelopmental Disorders.

Iman Imtiyaz Ahmed Juvale1, Ahmad Tarmizi Che Has2.   

Abstract

Neurodevelopmental disorders are defined as a set of abnormal brain developmental conditions marked by the early childhood onset of cognitive, behavioral, and functional deficits leading to memory and learning problems, emotional instability, and impulsivity. Autism spectrum disorder, attention-deficit/hyperactivity disorder, Tourette syndrome, fragile X syndrome, and Down's syndrome are a few known examples of neurodevelopmental disorders. Although they are relatively common in both developed and developing countries, very little is currently known about their underlying molecular mechanisms. Both genetic and environmental factors are known to increase the risk of neurodevelopmental disorders. Current diagnostic and screening tests for neurodevelopmental disorders are not reliable; hence, individuals with neurodevelopmental disorders are often diagnosed in the later stages. This negatively affects their prognosis and quality of life, prompting the need for a better diagnostic biomarker. Recent studies on microRNAs and their altered regulation in diseases have shed some light on the possible role they could play in the development of the central nervous system. This review attempts to elucidate our current understanding of the role that microRNAs play in neurodevelopmental disorders with the hope of utilizing them as potential biomarkers in the future.

Entities:  

Keywords:  Attention-deficit/hyperactivity disorder; Autism spectrum disorder; Down’s syndrome; Fragile X syndrome; MicroRNA; Tourette syndrome

Mesh:

Substances:

Year:  2021        PMID: 33774758     DOI: 10.1007/s12031-021-01825-7

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  194 in total

1.  Sequence variants in SLITRK1 are associated with Tourette's syndrome.

Authors:  Jesse F Abelson; Kenneth Y Kwan; Brian J O'Roak; Danielle Y Baek; Althea A Stillman; Thomas M Morgan; Carol A Mathews; David L Pauls; Mladen-Roko Rasin; Murat Gunel; Nicole R Davis; A Gulhan Ercan-Sencicek; Danielle H Guez; John A Spertus; James F Leckman; Leon S Dure; Roger Kurlan; Harvey S Singer; Donald L Gilbert; Anita Farhi; Angeliki Louvi; Richard P Lifton; Nenad Sestan; Matthew W State
Journal:  Science       Date:  2005-10-14       Impact factor: 47.728

2.  Young adult mental health and functional outcomes among individuals with remitted, persistent and late-onset ADHD.

Authors:  Jessica C Agnew-Blais; Guilherme V Polanczyk; Andrea Danese; Jasmin Wertz; Terrie E Moffitt; Louise Arseneault
Journal:  Br J Psychiatry       Date:  2018-06-29       Impact factor: 9.319

3.  Predicting young adult outcome among more and less cognitively able individuals with autism spectrum disorders.

Authors:  Deborah K Anderson; Jessie W Liang; Catherine Lord
Journal:  J Child Psychol Psychiatry       Date:  2013-12-09       Impact factor: 8.982

4.  N6-methyladenosine marks primary microRNAs for processing.

Authors:  Claudio R Alarcón; Hyeseung Lee; Hani Goodarzi; Nils Halberg; Sohail F Tavazoie
Journal:  Nature       Date:  2015-03-18       Impact factor: 49.962

5.  Chromosome 21-Encoded microRNAs (mRNAs): Impact on Down's Syndrome and Trisomy-21 Linked Disease.

Authors:  P N Alexandrov; M E Percy; Walter J Lukiw
Journal:  Cell Mol Neurobiol       Date:  2017-07-07       Impact factor: 5.046

6.  Regulation of divalent metal transporter 1 (DMT1) non-IRE isoform by the microRNA Let-7d in erythroid cells.

Authors:  Immacolata Andolfo; Luigia De Falco; Roberta Asci; Roberta Russo; Simona Colucci; Marisa Gorrese; Massimo Zollo; Achille Iolascon
Journal:  Haematologica       Date:  2010-04-21       Impact factor: 9.941

7.  Heterogeneous dysregulation of microRNAs across the autism spectrum.

Authors:  Kawther Abu-Elneel; Tsunglin Liu; Francesca S Gazzaniga; Yuhei Nishimura; Dennis P Wall; Daniel H Geschwind; Kaiqin Lao; Kenneth S Kosik
Journal:  Neurogenetics       Date:  2008-06-19       Impact factor: 2.660

8.  MicroRNA-195 protects against dementia induced by chronic brain hypoperfusion via its anti-amyloidogenic effect in rats.

Authors:  Jing Ai; Li-Hua Sun; Hui Che; Rong Zhang; Tian-Zhu Zhang; Wan-Chen Wu; Xiao-Lin Su; Xin Chen; Guang Yang; Kang Li; Ning Wang; Tao Ban; Ya-Nan Bao; Fei Guo; Hui-Fang Niu; Yu-Lan Zhu; Xiu-Ying Zhu; Shi-Guang Zhao; Bao-Feng Yang
Journal:  J Neurosci       Date:  2013-02-27       Impact factor: 6.167

9.  Comprehensive molecular testing in patients with high functioning autism spectrum disorder.

Authors:  Maria Isabel Alvarez-Mora; Rosa Calvo Escalona; Olga Puig Navarro; Irene Madrigal; Ines Quintela; Jorge Amigo; Dei Martinez-Elurbe; Michaela Linder-Lucht; Gemma Aznar Lain; Angel Carracedo; Montserrat Mila; Laia Rodriguez-Revenga
Journal:  Mutat Res       Date:  2016-01-06       Impact factor: 2.433

10.  Physical health in children with neurodevelopmental disorders.

Authors:  Setareh Alabaf; Christopher Gillberg; Sebastian Lundström; Paul Lichtenstein; Nóra Kerekes; Maria Råstam; Henrik Anckarsäter
Journal:  J Autism Dev Disord       Date:  2019-01
View more
  1 in total

1.  MicroRNAs serve as prediction and treatment-response biomarkers of attention-deficit/hyperactivity disorder and promote the differentiation of neuronal cells by repressing the apoptosis pathway.

Authors:  Liang-Jen Wang; Ho-Chang Kuo; Sheng-Yu Lee; Lien-Hung Huang; Yuyu Lin; Pei-Hsien Lin; Sung-Chou Li
Journal:  Transl Psychiatry       Date:  2022-02-19       Impact factor: 6.222

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.